Editas Medicine, Inc. (EDIT)
Last updated: 2026-10-21 22:53:40. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Summary
Editas Medicine, Inc. (EDIT) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $2.51, with a market capitalization of $371.66M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.66 to $4.21. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$371.66M | |
$2.59 | |
$99.95 | |
$0.91 | |
$2.58 | |
973.39K | |
2.58M | |
-- | |
$4.21 | |
$1.66 | |
-- | |
-- |
Editas Medicine, Inc. (EDIT) After-Hours Stock Price
Editas Medicine, Inc. (EDIT) is trading at $2.54 in after-hours trading as of 2026-10-21 22:41:00, down 1.63% ($0.04) from the regular-session close of $2.58.
After-hours trading shows how investors are pricing EDIT after the regular session closes. The current after-hours price is below the regular-session close, indicating cautious after-hours sentiment.
Editas Medicine, Inc. (EDIT) 7-Day Stock Price Change
Over the past seven days, Editas Medicine, Inc. (EDIT) moved from $2.75 to $2.51, representing a decline of 8.91% ($0.25).
The stock traded between $2.25 and $2.91 during the period. The latest price is near the middle of the 7-day range, indicating strong downward.
The average daily volume was 2.04 million shares, down versus the previous seven-day period, indicating lower trading activity.
EDIT 52-Week Price Position
Position in Range: 33.1%
EDIT is currently trading at $2.51, placing it 33.1% of the way from its 52-week low of $1.66 to its 52-week high of $4.21. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Editas Medicine, Inc. (EDIT)?
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
Editas Medicine, Inc. Information
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 87 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Editas Medicine, Inc. (EDIT) Stock on MEXC
Eligible investors can buy real shares of Editas Medicine, Inc. (EDIT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Editas Medicine, Inc. (EDIT) stock price today?
2.Is EDIT stock going up or down today?
3.What is EDIT pre-market price?
4.What is EDIT after-hours price?
5.Is EDIT stock trading now?
6.Where does EDIT sit relative to its 52-week high and low?
7.What sector is Editas Medicine, Inc. in?
8.What is Editas Medicine, Inc.'s market capitalization and where is it listed?
9.How is EDIT valued in terms of P/E ratio and EPS?
10.Does Editas Medicine, Inc. pay a dividend?
Explore More US Stocks
Search Stocks
EDIT Stock Calculator
Estimate the value between EDIT shares and USD.
EDIT Shares to USD
1.00 EDIT shares = 2.505 USD
Calculations are estimates based on the latest available price and are for reference only.


